Cover Image
Market Research Report
Product code 
1064437

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2022-2026

Published: | TechNavio (Infiniti Research Ltd.) | 120 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2022-2026
Published: March 3, 2022
TechNavio (Infiniti Research Ltd.)
Content info: 120 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Technavio has been monitoring the BCL-2 (B-cell Lymphoma 2) inhibitors market and it is poised to grow by $ 1.43 bn during 2022-2026, progressing at a CAGR of 12.60% during the forecast period. Our report on the BCL-2 (B-cell Lymphoma 2) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rise in geriatric population and growing awareness about hematological malignancies. In addition, rise in geriatric population is anticipated to boost the growth of the market as well.

The BCL-2 (B-cell Lymphoma 2) inhibitors market analysis includes the product segment and geographic landscape.

Technavio's BCL-2 (B-cell Lymphoma 2) inhibitors market is segmented as below:

By Product

  • Combination therapy
  • Monotherapy

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the high target affinity and specificity of BCL-2 inhibitorsas one of the prime reasons driving the BCL-2 (B-cell Lymphoma 2) inhibitors market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on BCL-2 (B-cell Lymphoma 2) inhibitors market covers the following areas:

  • BCL-2 (B-cell Lymphoma 2) inhibitors market sizing
  • BCL-2 (B-cell Lymphoma 2) inhibitors market forecast
  • BCL-2 (B-cell Lymphoma 2) inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading BCL-2 (B-cell Lymphoma 2) inhibitors market vendors that include AbbVie Inc., Ascentage Pharma Group International, AstraZeneca Plc, BioGene Ltd., F. Hoffmann La Roche Ltd., and Servier. Also, the BCL-2 (B-cell Lymphoma 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR72723

Table of Contents

1. Executive Summary

  • 1.1 Market Overview
  • Exhibit 01: Key Finding 1
  • Exhibit 02: Key Finding 2
  • Exhibit 03: Key Finding 3
  • Exhibit 04: Key Finding 5
  • Exhibit 05: Key Finding 6
  • Exhibit 06: Key Finding 7
  • Exhibit 07: Key Finding 8

2. Market Landscape

  • 2.1 Market ecosystem
    • 2.1.1 Parent Market
    • Exhibit 08 Parent market
  • Exhibit 09: Market characteristics
  • 2.2 Value Chain Analysis
  • Exhibit 10: Value Chain Analysis: Pharmaceuticals
    • 2.2.1 Research and development (R&D) and drug discovery:
    • 2.2.2 Integration and product development:
    • 2.2.3 Manufacturing:
    • 2.2.4 Outbound logistics:
    • 2.2.5 Marketing and sales:
    • 2.2.6 Support services:
    • 2.2.7 Innovation

3. Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021 - 2026
  • Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
  • Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)

4. Five Forces Analysis

  • 4.1 Five Forces Summary
  • Exhibit 15: Five forces analysis 2021 - 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 16: Bargaining power of the buyer
  • 4.3 Bargaining power of suppliers
  • Exhibit 17: Bargaining power of the supplier
  • 4.4 Threat of new entrants
  • Exhibit 18: Threat of new entrants
  • 4.5 Threat of substitutes
  • Exhibit 19: Threat of substitutes
  • 4.6 Threat of rivalry
  • Exhibit 20: Threat of rivalry
  • 4.7 Market condition
  • Exhibit 21: Market condition - Five forces 2021

5. Market Segmentation by Product

  • 5.1 Market segments
  • Exhibit 22: Product Market share 2021 - 2026 (%)
  • 5.2 Comparison by Product
  • Exhibit 23: Comparison by Product
  • 5.3 Combination therapy - Market size and forecast 2021-2026
  • Exhibit 24: Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 25: Combination therapy - Year-over-year growth 2021-2026 (%)
  • 5.4 Monotherapy - Market size and forecast 2021-2026
  • Exhibit 26: Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 27: Monotherapy - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Product
  • Exhibit 28: Market opportunity by Product

6. Customer landscape

    • Technavio-s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
  • 6.1 Overview
  • Exhibit 29: Customer landscape

7. Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 30: Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 31: Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 32: North America - Market size and forecast 2021-2026($ million)
  • Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe- Market size and forecast 2021-2026
  • Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 35: Europe- Year-over-year growth 2021-2026 (%)
  • 7.5 Asia- Market size and forecast 2021-2026
  • Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 37: Asia - Year-over-year growth 2021-2026(%)
  • 7.6 ROW - Market size and forecast 2021-2026
  • Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
  • Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
  • 7.7 Key leading countries
  • Exhibit 40: Key leading countries
  • 7.8 Market opportunity By Geographical Landscape
  • Exhibit 41: Market opportunity By Geographical Landscape ($ million)

8. Drivers, Challenges, and Trends

  • 8.1 Market drivers
    • 8.1.1 Rise in geriatric population
    • 8.1.2 Growing awareness about hematological malignancies
    • 8.1.3 High target affinity and specificity of BCL-2 inhibitors
  • 8.2 Market challenges
    • 8.2.1 Availability of substitutes
  • Exhibit 42: Some of the substitute drugs for BCL-2 inhibitor lead molecule:
    • 8.2.2 Adverse effects of BCL-2 inhibitors
    • 8.2.3 Drug resistance
  • Exhibit 43: Impact of drivers and challenges
  • 8.3 Market trends
    • 8.3.1 Increase of patient assistance programs
    • 8.3.2 Growing approval of combination therapy
    • 8.3.3 Development of novel formulations

9. Vendor Landscape

  • 9.1 Overview
  • Exhibit 44: Vendor landscape
  • 9.2 Landscape disruption
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Industry Risk
  • 9.3 Competitive Scenario

10. Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 47: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 48: Market positioning of vendors
  • 10.3 AbbVie Inc.
  • Exhibit 49: AbbVie Inc. - Overview
  • Exhibit 50: AbbVie Inc. - Product and service
  • Exhibit 51: AbbVie Inc. - Key offerings
  • 10.4 Ascentage Pharma Group International
  • Exhibit 52: Ascentage Pharma Group International - Overview
  • Exhibit 53: Ascentage Pharma Group International - Business segments
  • Exhibit 54: Ascentage Pharma Group International - Key offerings
  • Exhibit 55: Ascentage Pharma Group International - Segment focus
  • 10.5 AstraZeneca Plc
  • Exhibit 56: AstraZeneca Plc - Overview
  • Exhibit 57: AstraZeneca Plc - Product and service
  • Exhibit 58: AstraZeneca Plc - Key offerings
  • 10.6 BioGene Ltd.
  • Exhibit 59: BioGene Ltd. - Overview
  • Exhibit 60: BioGene Ltd. - Product and service
  • Exhibit 61: BioGene Ltd. - Key offerings
  • 10.7 F. Hoffmann La Roche Ltd
  • Exhibit 62: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 63: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 64: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 65: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.8 Servier
  • Exhibit 66: Servier - Overview
  • Exhibit 67: Servier - Business segments
  • Exhibit 68: Servier - Key offerings
  • Exhibit 69: Servier - Segment focus

11. Appendix

  • 11.1 Scope of the report
    • 11.1.1 Market definition
    • 11.1.2 Objectives
    • 11.1.3 Notes and caveats
  • 11.2 Currency conversion rates for US$
  • Exhibit 70: Currency conversion rates for US$
  • 11.3 Research Methodology
  • Exhibit 71: Research Methodology
  • Exhibit 72: Validation techniques employed for market sizing
  • Exhibit 73: Information sources
  • 11.4 List of abbreviations
  • Exhibit 74: List of abbreviations

Exhibits

  • Exhibits1: Key Finding 1
  • Exhibits2: Key Finding 2
  • Exhibits3: Key Finding 3
  • Exhibits4: Key Finding 5
  • Exhibits5: Key Finding 6
  • Exhibits6: Key Finding 7
  • Exhibits7: Key Finding 8
  • Exhibits8: Parent market
  • Exhibits9: Market characteristics
  • Exhibits10: Offerings of vendors included in the market definition
  • Exhibits11: Market segments
  • Exhibits12: Global - Market size and forecast 2021 - 2026 ($ million)
  • Exhibits13: Global market: Year-over-year growth 2021 - 2026 (%)
  • Exhibits14: Five forces analysis 2021 & 2026
  • Exhibits15: Bargaining power of buyers
  • Exhibits16: Bargaining power of suppliers
  • Exhibits17: Threat of new entrants
  • Exhibits18: Threat of substitutes
  • Exhibits19: Threat of rivalry
  • Exhibits20: Market condition - Five forces 2021
  • Exhibits21: Product - Market share 2021-2026 (%)
  • Exhibits22: Comparison by Product
  • Exhibits23: Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits24: Combination therapy - Year-over-year growth 2021-2026 (%)
  • Exhibits25: Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits26: Monotherapy - Year-over-year growth 2021-2026 (%)
  • Exhibits27: Market opportunity by Product
  • Exhibits28: Customer landscape
  • Exhibits29: Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits30: Geographic comparison
  • Exhibits31: North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits32: North America - Year-over-year growth 2021-2026 (%)
  • Exhibits33: Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits34: Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits35: Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits36: Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits37: ROW - Market size and forecast 2021-2026 ($ million)
  • Exhibits38: ROW - Year-over-year growth 2021-2026 (%)
  • Exhibits39: Key leading countries
  • Exhibits40: Market opportunity By Geographical Landscape ($ million)
  • Exhibits41: Impact of drivers and challenges
  • Exhibits42: Vendor landscape
  • Exhibits43: Landscape disruption
  • Exhibits44: Industry risks
  • Exhibits45: Vendors covered
  • Exhibits46: Market positioning of vendors
  • Exhibits47: AbbVie Inc. - Overview
  • Exhibits48: AbbVie Inc. - Product and service
  • Exhibits49: AbbVie Inc. - Key offerings
  • Exhibits50: AbbVie Inc. - Key customers
  • Exhibits51: AbbVie Inc. - Segment focus
  • Exhibits52: Ascentage Pharma Group International - Overview
  • Exhibits53: Ascentage Pharma Group International - Business segments
  • Exhibits54: Ascentage Pharma Group International - Key offerings
  • Exhibits55: Ascentage Pharma Group International - Key customers
  • Exhibits56: Ascentage Pharma Group International - Segment focus
  • Exhibits57: AstraZeneca Plc - Overview
  • Exhibits58: AstraZeneca Plc - Product and service
  • Exhibits59: AstraZeneca Plc - Key offerings
  • Exhibits60: AstraZeneca Plc - Key customers
  • Exhibits61: AstraZeneca Plc - Segment focus
  • Exhibits62: BioGene Ltd. - Overview
  • Exhibits63: BioGene Ltd. - Product and service
  • Exhibits64: BioGene Ltd. - Key offerings
  • Exhibits65: BioGene Ltd. - Key customers
  • Exhibits66: BioGene Ltd. - Segment focus
  • Exhibits67: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits68: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits69: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits70: F. Hoffmann La Roche Ltd. - Key customers
  • Exhibits71: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits72: Servier - Overview
  • Exhibits73: Servier - Business segments
  • Exhibits74: Servier - Key offerings
  • Exhibits75: Servier - Key customers
  • Exhibits76: Servier - Segment focus
  • Exhibits77: Currency conversion rates for US$
  • Exhibits78: Research Methodology
  • Exhibits79: Validation techniques employed for market sizing
  • Exhibits80: Information sources
  • Exhibits81: List of abbreviations